Scholarlink

Background <p> Limited data exist on seroconversion rates post-varicella vaccination in children with idiopathic nephrotic syndrome (NS).</p> Methods <p>This cross-sectional study assessed anti-varicella IgG antibodies (VZV-IgG) in idiopathic NS children aged 1–18&#xa0;years who were previously vaccinated (2 doses at a minimum 8-week interval), at least 3 months prior to enrolment. Exclusion criteria included secondary NS and eGFR &lt; 60&#xa0;mL/min/1.73&#xa0;m<sup>2</sup> at the time of vaccination. Baseline characteristics and seroconversion titres (VZV-IgG ≥ 110&#xa0;IU/L) by enzyme-linked immunosorbent assay (ELISA) kit were assessed.</p> Results <p>Two-hundred children with idiopathic NS (55.5% males) received varicella vaccine. The median interval between doses was 3&#xa0;months [IQR 2, 7], with a median age at vaccination of 6.8&#xa0;years [3.8, 9.8], and a median illness duration of 4.1&#xa0;years [1.7, 6.6]. Overall seroconversion rate was 64.5% with median VZV-IgG titres of 179 [IQR 62, 452] IU/L. The seroconversion was significantly associated with clinical phenotype when unadjusted for confounders. On univariate analysis, each additional relapse, children on levamisole post-vaccination, those on one second-line immunosuppressive agent, on two second-line immunosuppressive agents, and each additional month after vaccination were associated with 16%, 88%, 66%, 77%, and 3% significantly lower odds of seroconversion. The seroconversion rates or titres among those vaccinated within 4&#xa0;weeks of discontinuation of steroids were however not significantly different. Breakthrough varicella occurred in 1.5%. </p> Conclusions <p>To conclude, this study demonstrates that varicella vaccination confers seroprotection in approximately two-thirds of children with NS, with low rates of breakthrough varicella.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Seroconversion following varicella vaccination in children and adolescents with nephrotic syndrome

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Samith Ponnachan,
  • Bobbity Deepthi,
  • Rahul Dhodapkar,
  • Narayan Ramamurthy,
  • Sudarsan Krishnasamy,
  • Sriram Krishnamurthy

摘要

Background

Limited data exist on seroconversion rates post-varicella vaccination in children with idiopathic nephrotic syndrome (NS).

Methods

This cross-sectional study assessed anti-varicella IgG antibodies (VZV-IgG) in idiopathic NS children aged 1–18 years who were previously vaccinated (2 doses at a minimum 8-week interval), at least 3 months prior to enrolment. Exclusion criteria included secondary NS and eGFR < 60 mL/min/1.73 m2 at the time of vaccination. Baseline characteristics and seroconversion titres (VZV-IgG ≥ 110 IU/L) by enzyme-linked immunosorbent assay (ELISA) kit were assessed.

Results

Two-hundred children with idiopathic NS (55.5% males) received varicella vaccine. The median interval between doses was 3 months [IQR 2, 7], with a median age at vaccination of 6.8 years [3.8, 9.8], and a median illness duration of 4.1 years [1.7, 6.6]. Overall seroconversion rate was 64.5% with median VZV-IgG titres of 179 [IQR 62, 452] IU/L. The seroconversion was significantly associated with clinical phenotype when unadjusted for confounders. On univariate analysis, each additional relapse, children on levamisole post-vaccination, those on one second-line immunosuppressive agent, on two second-line immunosuppressive agents, and each additional month after vaccination were associated with 16%, 88%, 66%, 77%, and 3% significantly lower odds of seroconversion. The seroconversion rates or titres among those vaccinated within 4 weeks of discontinuation of steroids were however not significantly different. Breakthrough varicella occurred in 1.5%.

Conclusions

To conclude, this study demonstrates that varicella vaccination confers seroprotection in approximately two-thirds of children with NS, with low rates of breakthrough varicella.

Graphical abstract